Adolescents with overweight or obesity and asthma taking a GLP-1 agent had less risk of asthma exacerbations compared with ...
Flow Space on MSN
Update: FDA approves oral version of Wegovy, first GLP-1 pill approved specifically for weight management
Just before the end of 2025, an oral version of a GLP-1 drug specifically used for weight management moved much closer to ...
Families using GLP-1s are spending less on food, from grocery stores to restaurants, according to a study published Dec. 18 ...
Novo Nordisk plans to quickly launch the pill form of Wegovy but is expected to soon face competition from Eli Lilly.
Both Novo Nordisk’s and competitor Eli Lilly’s injectable GLP-1 drugs, Wegovy and Zepbound, have helped transform obesity ...
Expanded use of GLP-1 drugs may lead to more side effects, already the subject of thousands of lawsuits now moving through ...
The FDA has approved the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for weight loss and to reduce the risk ...
The U.S. Food and Drug Administration has approved Novo Nordisk’s Wegovy® pill, making it the first and only oral GLP-1 ...
The next transformative phase of weight-loss medication is upon us, with the US Food and Drug Administration (FDA) approving ...
ITHACA, NY. — The impact of GLP-1 medications on consumer food spending is meaningful, according to new research published by ...
Jonathan Van Ness is showing off his figure after openly discussing his GLP-1 weight loss. “Sorry not sorry for leading with ...
A growing body of research suggests that older adults are discontinuing GLP-1 medications at high rates, The New York Times reported Dec. 21. Six things to know: 1. Sixty percent of Americans over age ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback